202 related articles for article (PubMed ID: 1972688)
1. Clinical evaluations of the tumor marker sialyl SSEA-1 antigen for clinical gynecological disease.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Karino K; Endoh J; Kitao M
Gynecol Obstet Invest; 1990; 29(3):214-8. PubMed ID: 1972688
[TBL] [Abstract][Full Text] [Related]
2. [The clinical significance of serum sialyl SSEA-1 antigen in obstetrical and gynecological patients].
Tanaka T; Iwasaka T; Hayashi Y; Hachisuga T; Yokoyama M; Ohkuma Y; Matsuo N; Fukuda K; Sugimori H
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1157-61. PubMed ID: 1975831
[TBL] [Abstract][Full Text] [Related]
3. Differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Takahashi K; Yoshino N; Karino K; Endoh J
Gynecol Obstet Invest; 1990; 29(1):71-4. PubMed ID: 1972127
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of sialyl SSEA-1 antigen in patients with ovarian cancer.
Suzuki M; Ohwada M; Tamada T
Gynecol Oncol; 1990 Mar; 36(3):371-5. PubMed ID: 1969379
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels].
Iwanari O; Miyako J; Date Y; Moriyama M; Yoshino N; Kijima S; Nakayama S; Ryuhkoh K; Moriyama M; Hata T
Nihon Gan Chiryo Gakkai Shi; 1989 Jun; 24(6):1256-60. PubMed ID: 2571650
[TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of the combination assay of CA 125, SLX, and CA 72-4 in patients with ovarian cancer].
Kobayashi H; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1731-5. PubMed ID: 2574209
[TBL] [Abstract][Full Text] [Related]
7. [The clinical value of sialyl SSEA-1 antigen in patients with gynecologic tumors].
Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saitoh J; Ueda G; Tanizawa O; Kimura T; Kawata M; Taniguchi T
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Dec; 39(12):2120-4. PubMed ID: 2892886
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of serum sialyl SSEA-1 antigen levels in patients with epithelial ovarian cancer. Comparative effectiveness of sialyl SSEA-1 and CA 125.
Kobayashi H; Kawashima Y
Gynecol Obstet Invest; 1990; 30(1):52-8. PubMed ID: 1977666
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
Iwasaka T; Ohkuma Y; Yoshimura T; Sugimori H
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer--a study on 674 patients.
Takahashi K; Shibukawa T; Moriyama M; Shirai T; Kijima S; Iwanari O; Matsunaga I; Kitao M
Jpn J Surg; 1986 Sep; 16(5):305-10. PubMed ID: 3467109
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of serum sialyl SSEA-1 (SLX) in diagnosis of cancers].
Kawakami H; Sawabu N; Takemori Y; Okai T; Motoo Y; Satomura Y; Ohta H; Watanabe H; Matsuda N; Yamakawa O
Nihon Shokakibyo Gakkai Zasshi; 1989 May; 86(5):1141-8. PubMed ID: 2571740
[TBL] [Abstract][Full Text] [Related]
12. [The clinical usefulness of the measurement of serum sialyl SSEA-1 antigen levels in patients with gynecologic diseases: as respects the comparative effectiveness of sialyl SSEA-1 and CA125].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):828-34. PubMed ID: 3166483
[TBL] [Abstract][Full Text] [Related]
13. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies.
Avall Lundqvist E; Nordström L; Sjövall K; Eneroth P
Eur J Gynaecol Oncol; 1989; 10(6):395-405. PubMed ID: 2627971
[TBL] [Abstract][Full Text] [Related]
16. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].
Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3221-30. PubMed ID: 2571323
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
[TBL] [Abstract][Full Text] [Related]
18. [Value of SLX and CA19-9 in the serum and tissue in colorectal cancer including the relation to Lewis blood type].
Igarashi K
Nihon Shokakibyo Gakkai Zasshi; 1989 Oct; 86(10):2394-403. PubMed ID: 2574243
[TBL] [Abstract][Full Text] [Related]
19. [Clinical usefulness of serum sialyl Le(x)-i measurement in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):15-9. PubMed ID: 2564410
[TBL] [Abstract][Full Text] [Related]
20. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
